Pierre Fabre Pharmaceuticals agrees FDA path for tabelecleucel BLA resubmission
Updated
Updated · PR Newswire · May 7
Pierre Fabre Pharmaceuticals agrees FDA path for tabelecleucel BLA resubmission
10 articles · Updated · PR Newswire · May 7
After a Type A meeting, the company said it will finalise plans within weeks and submit updated Phase 3 ALLELE data with more patients and longer follow-up.
The FDA agreed a single-arm study with a pre-specified historical control could provide adequate safety and efficacy evidence for the proposed marketing application.
Tabelecleucel targets relapsed or refractory EBV-positive post-transplant lymphoproliferative disease after prior anti-CD20 therapy, an ultra-rare lymphoma with no FDA-approved treatment and survival often measured in weeks to months after standard treatment fails.
For an ultra-rare lymphoma with no options, is a trial without a control group good enough for FDA approval?
Could this donor-cell therapy set a new standard for treating rare diseases, or will its risks outweigh the benefits?
FDA Rejects Pierre Fabre’s Tabelecleucel BLA in 2026, Demands New Controlled Trial Despite EMA Approval
Overview
In January 2026, the FDA issued a Complete Response Letter rejecting Pierre Fabre's tabelecleucel application, reversing its prior acceptance of the ALLELE trial data and requiring a new controlled study. Despite resolved manufacturing issues and consistent positive real-world data from Europe and U.S. expanded access programs, the FDA's demand caused significant delays in patient access and placed Atara Biotherapeutics under financial strain. Pierre Fabre responded by requesting a Type A meeting, after which the FDA indicated approval might be possible if the ALLELE data is strengthened with a rigorous historical control. This case highlights growing FDA caution toward single-arm trials in rare diseases, fueling industry uncertainty and patient advocacy efforts.